Stelara, NorLevo move closer to final Japanese approval
This article was originally published in Scrip
Janssen Pharmaceutical's biologic therapy Stelara (ustekinumab) and Sosei's emergency oral contraceptive (OC) NorLevo (levonorgestrel; SOH-075) have been given positive approval recommendations in Japan, moving them closer to commercialisation in what is likely to become an important market.
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.